The FDA accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release and donepezil hydrochloride tabilized on memantine hydrochloride and donepezil hydrochloride

“Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy.  Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate/severe Alzheimer’s disease.”

Dr. Neil Buckholtz of the NIA discusses ADNI in a summary of the recent presentations at the AAIC in Copenhagen and other Alzheimer’s research news.

From early morning to late evening, at symposium and plenary sessions, during poster sessions and coffee breaks, at add-on meetings and consortium sessions, some 4,300 investigators from 75 different countries shared recent findings and explored ways to overcome the challenges of finding ways to treat or prevent this complex disease.

A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer’s disease involving the so-called retromer protein complex.

Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer’s.